References
- 1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
- 2. Kurien B, Hensley K, Bachmann M, Scofield R. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med. 2006;41(4):549-56.
- 3. Griffiths H. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease. Autoimmun Rev. 2008;7(7):544-49.
- 4. Filippin L, R.Vercelino, Marroni N, Xavier R. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol. 2008;152:415-22.
- 5. Hassan S, Gheita T, Kenawy S, Fahim A, El- Sorougy I, Abdou M. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis. 2011;14(4): 325-31.
- 6. Mansour B, Lassoued S, Elgaied A, Haddouk S, Marzouk S, Bahloul Z, et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol. 2010;39(3):247-53.
- 7. Kurien B, Scofield R. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev. 2008;7(7):567-73.
- 8. Matsuuraa E, Hughes G, Khamashta M. Oxidation of LDLand its clinical implication Autoimmun Rev. 2008;7(7):558-66.
- 9. Filippin L, Vercelino R, Marroni N, Xavier R. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol. 2008;152:415-22.
- 10. Elsalakawy W, Ali M, Hegazy M, Farweez B. Value of vanin-1 assessment in adult patients with primary immune thrombocytopenia. Platelets. 2014;25(2):86-92.
- 11. Zhang B, Lo C, Shen L, Sood R, Jones C, Cusmano-Ozog K, et al. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood. 2011;117:4569-79.
- 12. Cines D. Pathogenesis of ITP. In: Cines D, Kuter D, Newland A, Provan D, Semple J, editors. The Handbook-Immune Thrombocytopenia. 1st ed. Genoa: European School of Haematology; 2011. p. 77-87.
- 13. Cines D, Bussel J, Liebman H, Luning P. The ITPsyndrome: Pathogenic and clinical diversity. Blood. 2009;113:6511-21.
- 14. Kamhieh-Milz J, Bal G, Sterzer V, Kamhieh-Milz S, Arbach O, Salama A. Reduced antioxidant capacities in platelets from patients with autoimmune thrombocytopenia purpura (ITP). Platelets. 2012;23:184-94.
- 15. Jin CQ, Dong HX, Cheng PP, Zhou JW, Zheng BY, Liu F. Antioxidant status and oxidative stress in patients with chronic ITP. Scand J Immunol. 2013;77:482-7.
- 16. Akbayram S, Dogan M, Akgun C, Mukul Y, Peker E, Bay A, et al. The association of oxidant status and antioxidant capacity in children with acute and chronic ITP. J Pediatr Hematol Oncol. 2010;32(4):277-81.
- 17. Polat G,Tamer L,Tanriverdi K, Gurkan E, Baslamisli F, Atik U. Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura. East Afr Med J. 2002;79(8):446-9.
- 18. Kamhieh-Milz J, Salama A. Oxidative stress is predominant in female but not in male patients with autoimmune thrombocytopenia. Oxid Med Cell Longev. 2014;2014:720347.